Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Assembly Biosciences Inc (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011824
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbiotic therapies for Clostridium difficile (C. difficile) infections (CDI). It also develops Gemicel platform technology that helps for targeted oral delivery vaccines, live biotherapeutics, small molecules and complex macromolecules which are aimed for specific region in gastrointestinal tract(GI). Assembly’s HBV Cure program target’s the chronic hepatitis B virus infection. The company has research and development facilities in New York, Indiana and California. Assembly is headquartered in Carmel, Indiana, the US.

Assembly Biosciences Inc (ASMB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Merger 11
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Licensing Agreements 12
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Equity Offering 17
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc – Key Competitors 29
Assembly Biosciences Inc – Key Employees 30
Assembly Biosciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jul 28, 2017: Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 32
Jan 11, 2016: Assembly Biosciences Expands Senior Leadership Team 33
Product News 35
01/27/2016: Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel Technology Achieves Targeted Delivery to the Lower GI Tract 35
Clinical Trials 36
Sep 25, 2017: Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development 36
Nov 09, 2016: Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc, Key Competitors 29
Assembly Biosciences Inc, Key Employees 30
Assembly Biosciences Inc, Other Locations 31
Assembly Biosciences Inc, Subsidiaries 31

★海外企業調査レポート[Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PT Tiphone Mobile Indonesia Tbk (TELE):企業の財務・戦略的SWOT分析
    PT Tiphone Mobile Indonesia Tbk (TELE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • China Hi-Tech Group Co. Ltd. (600730):企業財務及び戦略的SWOT分析
    Summary China Hi-Tech Group Co. Ltd. (China Hi-Tech), formerly China Hi-Tech Group Company is a diversified company that offers development strategy, education, commodity trading, investment property and asset management. Its asset management services includes use of financial investment and strateg …
  • Telephone and Data Systems, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Telephone and Data Systems, Inc …
  • Tong Ren Tang Technologies Co Ltd (1666):企業財務及び戦略的SWOT分析
    Summary Tong Ren Tang Technologies Co Ltd (TRTT), a subsidiary of Beijing Tong Ren Tang Group Co., Ltd. is a manufacturer and supplier of Chinese medicines. The company’s products include Chinese medicine, healthy food and maier hai cosmetics. It offers products in the forms of pills, tablets, granu …
  • DHG Pharmaceutical (DHG):企業財務及び戦略的SWOT分析
    Summary DHG Pharmaceutical (DHG Pharma) formerly Hau Giang Pharmaceutical Joint Stock Company is a nutritional and healthcare company that offers dietary products. The company manufactures and sells pharmaceuticals, dietary supplement, and cosmetics products. It provides antibiotic, antifungal – ant …
  • Guided Therapeutics, Inc. (GTHP):企業のM&A・提携動向(医療機器分野)
    Summary Guided Therapeutics, Inc. (GTI) is a biotechnology company that offers platform technology. The company offers products for the non-invasive cervical cancer detection markets. It develops technology to painlessly detect disease before it becomes cancer. The company’s products include luviva …
  • IFA Hotels and Resorts Company KSCC:企業の戦略・SWOT・財務情報
    IFA Hotels and Resorts Company KSCC - Strategy, SWOT and Corporate Finance Report Summary IFA Hotels and Resorts Company KSCC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Swissquote Group Holding Ltd (SQN):企業の財務・戦略的SWOT分析
    Swissquote Group Holding Ltd (SQN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Tonix Pharmaceuticals Holding Corp (TNXP):製薬・医療:M&Aディール及び事業提携情報
    Summary Tonix Pharmaceuticals Holding Corp (Tonix) is a developer of pharmaceutical products to address public health challenges. The company offers pharmaceutical products and treatments for disorders of the central nervous system including fibromyalgia, post traumatic stress disorder and episodic …
  • Hitachi Zosen Corporation (7004):企業のM&A・提携動向(発電分野)
    Summary Hitachi Zosen Corporation (Hitachi Zosen) is a manufacturer of heavy industrial machinery. It conducts design and construction of process equipment, environmental systems, industrial plants, infrastructure-related equipment, disaster prevention systems, water treatment system, industrial mac …
  • CML Microsystems PLC (CML):企業財務及び戦略的SWOT分析
    Summary CML Microsystems PLC (CML Microsystems) is an electronic equipment company that designs, manufactures and distributes semiconductor products. The company's products include ICs covering radio frequency; flash controller IC, and voice, data and signaling ICs. Its radio frequency ICs are used …
  • Spark Therapeutics Inc (ONCE):企業財務及び戦略的SWOT分析
    Summary Spark Therapeutics Inc (Spark) is a pharmaceutical company that develops gene therapy products for the treatment of debilitating genetic diseases such as inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. The company’s gene therapy vectors used in its progra …
  • Van Oord nv:企業のM&A・提携動向(石油・ガス分野)
    Summary Van Oord nv (Van Oord) is a contracting company specialized in dredging, marine engineering and offshore projects including oil, gas and wind. The company's core activities include dredging, offshore oil and gas and offshore wind projects. Its major activities include creation of artificial …
  • Green Bridge Industries, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Green Bridge Industries, Inc. M …
  • Deutsche Beteiligungs AG:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Deutsche Beteiligungs AG Merger …
  • Birner Dental Management Services, Inc. (BDMS):企業概要、財務及び戦略的SWOT分析
    Summary Birner Dental Management Services, Inc. (BDMS) is a healthcare management company. The company provides dental services, including orthodontics, oral surgery, periodontics and endodontic, as well as pediatrics and emergency services. It offers solutions to dentists, patients, and third-party …
  • Air France-KLM SA:戦略・SWOT・企業財務分析
    Air France-KLM SA - Strategy, SWOT and Corporate Finance Report Summary Air France-KLM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Biom’Up SAS (BUP):医療機器:M&Aディール及び事業提携情報
    Summary Biom'Up SAS (Biom'Up) is a medical device company that designs, develops and manufactures collagen-based absorbable medical devices for biosurgery. The company's products include covamesh, hemosnow, hemoblast bellows, cova and matri bone, among others. It offers collagens, resorbable polymer …
  • Yamashita Medical Instruments Co., Ltd. (3022):企業財務及び戦略的SWOT分析
    Summary Yamashita Medical Instruments Co., Ltd. (Yamashita Medical) is a medical device company that offers sale, rental and leasing of various medical equipment. The company also sells scientific instruments, medical office computer, medical equipment instrument, animals for medical equipment, and …
  • Alphageo India Limited (ALPHAGEO):企業財務及び戦略的SWOT分析
    Summary Alphageo India Limited (Alphageo) is an oil and gas company that provides seismic survey services. The company operates through its segments such as oil exploration and production. Its services comprise design and preplanning, seismic data acquisition, seismic data processing and reprocessin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆